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Abstract
Thymosin b10 (Tb10) regulates actin dynamics as a cytoplasm G-actin sequestering protein. Previously, we have shown that
Tb10 diminishes tumor growth, angiogenesis, and proliferation by disrupting actin and by inhibiting Ras. However, little is
known about its mechanism of action and biological function. In the present study, we establish a new gene therapy model
using a genetically modified adenovirus, referred to as Ad.TERT.Tb10, that can overexpress the Tb10 gene in cancer cells. This
was accomplished by replacing the native Tb10 gene promoter with the human TERT promoter in Ad.TERT.Tb10.W e
investigated the cancer suppression activity of Tb10 and found that Ad.TERT.Tb10 strikingly induced cancer-specific
expression of Tb10 as well as apoptosis in a co-culture model of human primary ovarian cancer cells and normal fibroblasts.
Additionally, Ad.TERT.Tb10 decreased mitochondrial membrane potential and increased reactive oxygen species (ROS)
production. These effects were amplified by co-treatment with anticancer drugs, such as paclitaxel and cisplatin. These
findings indicate that the rise in ROS production due to actin disruption by Tb10 overexpression increases apoptosis of
human ovarian cancer cells. Indeed, the cancer-specific overexpression of Tb10 by Ad.TERT.Tb10 could be a valuable anti-
cancer therapeutic for the treatment of ovarian cancer without toxicity to normal cells.
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Introduction
Thymosins are a family of small proteins that were originally
isolated from calf thymus, and are divided into three classes (a,
b and c) based on their isoelectric point [1]. The b-thymosins,
which have an average molecular mass of roughly 5 kDa, are
highly conserved acidic proteins that are found in almost every
eukaryotic cell. The b-thymosins inhibit barbed end actin
polymerization by sequestering actin monomers [2,3]. As one of
the most abundant b-thymosins in mammalian species, thymo-
sin b10 (Tb10) affects metastasis and proliferation in many
cancer cells [4–6]. The anti-cancer effects of Tb10 appear to be
closely related to its function as a regulator of actin dynamics in
tumor cells [7,8]. Actin dynamics can be perturbed by the
addition of actin-stabilizing drugs or the introduction of
mutations, causing changes in cellular architecture and internal
cellular movement. Furthermore, recent reports have indicated
that changes in actin dynamics can result in the release of
reactive oxygen species (ROS) from mitochondria and sub-
sequent cell death, emphasizing the importance of maintaining
the dynamic regulation of the actin cytoskeleton [9–14].
Recently, telomerase has been recognized as a wide-range
tumor marker and is now considered one of the most important
therapeutic targets for cancer treatment. Human telomerase
reverse transcriptase (hTERT), the catalytic subunit of telomer-
ase, is detected in approximately 90% of cancer cells from
tumor tissue, but is not detectable in normal tissues [15–17].
Previous studies have demonstrated that the hTERT promoter
can regulate the ectopic expression of genes of interest in
telomerase-positive cancer cells, indicating that the hTERT
promoter is a promising candidate for generating cancer-specific
adenoviruses [18–22].
Here, we describe a recombinant adenovirus, Ad.-
TERT.Tb10, that was constructed by inserting the Tb10 gene
under the control of the hTERT gene promoter into the
adenovirus p-shuttle plasmid to induce tumor-specific Tb10 gene
expression. We also established a co-culture model of primary
human ovarian cancer cells and normal fibroblasts and sub-
sequently treated this co-culture with Ad.TERT.Tb10 to
elucidate the cancer-specific effects of Ad.TERT.Tb10.I n
addition, we investigated the mechanism of Tb10-induced
apoptosis in 2774 human ovarian cancer cells that were treated
with Ad.TERT.Tb10. These experiments revealed evidence that
Ad.TERT.Tb10 induces cancer-specific expression of Tb10,
thereby resulting in cancer-specific apoptosis through ROS
production. Together these findings indicate that the cancer-
specific overexpression of Tb10 by Ad.TERT.Tb10 could indeed
be a valuable anti-cancer therapeutic for the treatment of
ovarian cancer without toxicity to normal cells and possibly
other malignancies.
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Thymosin b10 is Expressed at Low Levels in Ovarian
Cancer
In our previous study, we reported that Tb10 mRNA levels were
elevated in normal ovaries, as compared to other tissues, such as
spleen, thymus, prostate, testis, small intestine, colon, and
peripheral blood leukocytes, but the mRNA levels of Tb10 were
decreased in ovarian cancers [23]. We, therefore, confirmed the
mRNA and protein expression levels of thymosin b10 (Tb10)i n
serous type ovarian cancer and mucinous type ovarian cancer, as
well as in cervical cancer and immortalized ovarian cancer cell
lines, such as 2774, OVCAR3, and SKOV3. Our findings that
mRNA (Figure 1A) and protein (Figure 1B) levels of Tb10 were
high in normal ovarian tissue, but decreased in all of Serous
Carcinoma, Mucinous Carcinoma, and the immortalized ovarian
cancer cell lines, were consistent with our previous study.
However, we were unable to detect changes in normal cervical
tissue, adenocarcinomas, and squamous cell carcinomas. Notably,
high expression levels of Tb10 are characteristic of normal ovaries,
but these levels decrease in ovarian cancer, suggesting that Tb10
plays a role in ovarian cancer development.
Cancer-specific Expression of Thymosin b10 by
Ad.TERT.Tb10
To elucidate the role of Tb10 in human ovarian cancer, we
established a new physiological model by co-culturing primary
ovarian cancer cells with normal fibroblasts and using a cancer-
specific gene delivery system comprising a genetically modified
adenovirus. We constructed recombinant adenovirus, Ad.-
TERT.Tb10, by replacing the Tb10 gene promoter with the
hTERT promoter, and we confirmed the integrity of Ad.-
TERT.Tb10 by polymerase chain reaction (PCR) using Ad-
TERT, Tb10, and E1a primers (Figure 2A). To confirm the level
of Tb10 gene expression, we treated 2774 cells with Ad.-
TERT.Tb10 at a multiplicity of infection (MOI) of 10 and then
monitored changes in the Tb10 expression using immunocyto-
chemistry (ICC) and RT-PCR. Our results revealed that
Ad.TERT.Tb10 elevated Tb10 expression in the cytosol
(Figure 2B).
We also evaluated cancer-selective induction of gene expression
by recombinant adenoviruses, Ad.TERT.Tb10 and Ad.TER-
T.LacZ, on our co-culture model of primary ovarian cancer cells
and normal fibroblasts. On day 7 after treatment with 10 MOI of
Ad.TERT.LacZ, we observed that ovarian cancer cells had grown
well on the layer formed by normal fibroblast cells like being
observed in untreated group. Furthermore, X-gal positive cells,
indicating b-galactosidase expression by Ad.TERT.LacZ, were
detected only in primary ovarian cancer cells (Figure 2C). On day
1 after treatment with Ad.TERT.Tb10, green fluorescence,
indicating Tb10 expression, was detected in primary ovarian
cancer cells but not in normal fibroblast cells (Figure 2D),
suggesting that the TERT promoter confers ovarian cancer-
specific gene expression.
Effects of Thymosin b10 on Ovarian Cancer Cell Migration
Previous reports demonstrated that the anti-cancer effects of
Tb10 are closely related to its role in regulating actin dynamics in
tumor cells [7,8]. We, therefore, examined the role of Tb10 in
cancer cell migration and invasion. We found that both cancer cell
migration and invasion were significantly decreased in the
2774 cells infected by Ad.TERT.Tb10, in comparison with
2774 cells infected with Ad.TERT.LacZ and uninfected 2774 cells
(Figure 3A). In relation to cell migration, cell movement was also
estimated by wound-healing assay. 2774 cell motility on a plastic
surface was significantly reduced by Ad.TERT.Tb10 treatment
(Figure 3B).
Induction of Cancer-specific Apoptosis by
Ad.TERT.Thymosin b10
To examine the effects of overexpression of Tb10 on cancer cell
viability, subconfluent 2774 ovarian cancer cells were infected with
Ad.TERT.LacZ or Ad.TERT.Tb10 at an MOI of 10, and the
MTT-bioassay was performed daily for 6 days. We found that
Tb10 significantly decreased ovarian cancer cell viability, when
compared with media controls with or without Ad.TERT.LacZ
(Figure 4A). Next, to examine whether the decrease in cell viability
was due to apoptosis, we performed FACS analysis for Annexin V-
FITC and found that overexpression of Tb10 induced apoptosis,
but not necrosis, in the 2774 ovarian cancer cell line (Figure 4B).
Moreover, on day 1 after treatment of Ad.TERT.Tb10 in co-
culture model of primary human ovarian cancer with normal
fibroblasts, we clearly observed nuclear fragmentation (blue
fluorescence) only in ovarian cancer cells that overexpressed
Tb10 (green fluorescence). Moreover, we were unable to detect
nuclear fragmentation or Tb10 expression above background levels
the normal fibroblast. These results indicate that cancer-specific
overexpression of Tb10, which is facilitated by the TERT
promoter, stimulates cancer-specific nuclear fragmentation as
one of the morphological hallmarks of apoptosis (Figure 5A). In
addition we observed striking morphological changes of ovarian
cancer cells treated with Ad.TERT.Tb10 for over 90 hr using
a real-time imaging microscope. After 10 hours of treatment with
Ad.TERT.Tb10, we observed typical apoptotic morphological
changes in the ovarian cancer cells such as plasma membrane
blebbing, loss of cell-cell interactions, cytoplasmic vacuolization,
and cell shrinkage due to the rapid dehydration. Apoptotic cells
gradually disappeared by cell death, whereas normal fibroblast
cells seemed to be unaffected by Ad.TERT.Tb10 for over 90 hr
(Figure 5B; Movie S1).
The Relationship Between Thymosin b10 and Fas
Expression
To examine whether ovarian cancer-specific apoptosis is due to
apoptosis-promoting gene expression and subsequent signal trans-
duction, we assessed Fas expression and caspase 3 activation using
primary ovarian cancer cells co-cultured with normal fibroblasts as
well as the 2774 ovarian cancer cell line. We found that
Ad.TERT.Tb10 induced Fas mRNA and protein expression in
2774 ovarian cancer cells (Figure 6A). In the primary co-culture
model, Fas expression was detected in primary ovarian cancer cells
but not in normal fibroblasts. These findings are consistent with
the cancer-specific expression of Tb10 after infection with
Ad.TERT.Tb10 (Figure 6B). Importantly, Tb10 increased caspase
3 activity as did Cytochalasin D (Cyt D), a potent inhibitor of actin
polymerization. The increased caspase 3 activity was also inhibited
by the addition of caspase inhibitor Z-VAD-FMK. Furthermore,
these data are consistent with the cell viability results obtained
from the alarmar Blue assay (Figure 6C).
The Effects of Thymosin b10 on Mitochondrial
Dysfunction and ROS Production
Previous reports have indicated that disruption of the actin
cytoskeleton induces the extracellular generation of ROS, in
particular O2
-, which amplifies Fas-dependent apoptosis [13,24].
In addition, decreased actin dynamics cause depolarization of the
mitochondrial membrane and an increase in ROS production,
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inhibition of actin polymerization by Tb10 opens mitochondrial
membrane pores or channels for a prolonged time, resulting in
reduction of the mitochondrial membrane potential (MMP) and
an increase in the release of ROS into the cytoplasm. Therefore,
we measured Tb10-induced changes in MMP ROS levels and
found that initially high levels of MMP were markedly decreased
by Tb10 overexpression (Figure 7A). Moreover, ROS production
was increased by Tb10 overexpression, which is consistent with the
result of the MTT bioassay.
It has been reported that cellular ROS levels increase under
conditions of stress by treatment with anticancer agents such as
taxol (paclitaxel) and platinum (cisplatin). This ROS increase
leads to the induction of proapoptotic molecules, such as p53
and mitogen-activated protein kinases (MAPKs), leading to
cellular apoptosis [25–30]. We used Ad.TERT.Tb10 as a co-
treatment with two classes of the anticancer agents, and found
that the co-treatment resulted in synergistic effects, increasing
ROS generation and decreasing cell viability (figure 7B). These
findings suggest that ovarian cancer apoptosis induced by Tb10
overexpression is due to ROS production in response to
decreased MMP.
Discussion
Of the ß-thymosin family members, thymosin ß4 (Tb4),
thymosin ß10 (Tb10), and thymosin ß15 (Tb15) have been studied
in carcinogenesis. They have been implicated in actin sequestra-
Figure 1. Comparison of endogenous mRNA and protein expression in the human ovary, cervix, and various cancer cell types. (A)
mRNA expression levels of Tb10 were determined by real-time PCR using total RNA isolated from human normal and cancer tissues including ovarian
cancer cell lines, such as serous carcinoma (Serous. C) and mucinous carcinoma (Mucinous. C), immortalized human ovarian cancer cell lines (2774,
OVCAR3, and SKOV3), and adenocarcinoma (Adeno. C) and squamous cell carcinomas (Squamous Cell. C) of the cervix. Data is presented as mean 6
SE for n=3 separate samples per cell type grouping and is expressed in terms of percentage of normal ovary. Significant differences between groups
are denoted by an asterisk (*), P,0.05; a double asterisk (**), P,0.01 (B) The protein expression level of Tb10 was determined by
immunohistochemistry in normal ovary tissue and compared with that in serous and mucinous types of ovarian cancer, respectively.
doi:10.1371/journal.pone.0035399.g001
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and their role in neoplastic disease progression remains contro-
versial.
The elevated expression of Tb4 and Tb10 has been regarded as
a characteristic of human carcinogenesis. Overexpression of Tb4
occurs in a wide variety of human carcinomas. Tb4 affects
Figure 2. Construction of a recombinant adenovirus vector based on the AdEasy
TM system and confirmation of cancer-specific
gene introduction by the recombinant adenovirus (Ad.TERT.Tb10). (A) Schematic diagram of the recombinant adenovirus, Ad.TERT.Tb10,
generated by recombination of pSuttle.TERT.Tb10 and the backbone plasmid pAdEasy-1 in BJ5183. The modified pShuttle plasmid, referred to as
pSuttle.TERT.Tb10, was cloned by orderly insertion of the human TERT promoter and Tb10 gene to generate a recombinant adenovirus. The integrity
of Ad.TERT.Tb10 was determined by polymerase chain reaction (PCR) using primers Ad-TERT, Tb10, and E1a. (B) Subconfluent 2774 ovarian cancer cells
were infected with 10 MOI of Ad.TERT.LacZ or Ad.TERT.Tb10. After 24 hr, Tb10 protein and mRNA levels were determined by immunocytochemistry
and RT-PCR, respectively. (C) Subconfluent primary human ovarian cancer cells co-cultured with fibroblast cells were exposed to 10 MOI of
Ad.TERT.LacZ for 7 days. b-galactosidase expression level was determined by b-gal staining (blue color). Arrow at center of figure indicates a primary
ovarian cancer cell mass. (D) Subconfluent primary human ovarian cancer cells co-cultured with fibroblast cells were also exposed to 10 MOI of
Ad.TERT.Tb10 for 24 hr. Tb10 expression level was determined by immunocytochemistry (green color). Arrows at the bottom of figure indicate primary
ovarian cancer cells.
doi:10.1371/journal.pone.0035399.g002
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[31–34]. Likewise, overexpression of Tb10 has been reported in
numerous human carcinomas, including melanomas [1], carcino-
mas of the kidney, pancreas [35], and stomach [36], as well as
medullary thyroid carcinomas [37].
Paradoxically, Tb4 and Tb10 may be involved in cancer
degeneration, as reports have indicated that Tb4 has tumor
suppressive effects in myeloma [38], and Tb10 is deregulated in
renal cell carcinoma [39] and ovarian cancer [40]. In addition,
Tb10 inhibited cell migration and capillary-like tube formation of
human coronary artery endothelial cells [6]. Our findings also
implicate Tb10 in cancer degeneration, as the high level of Tb10
transcripts in normal ovary was remarkably reduced in ovarian
carcinomas. Moreover, ectopic expression of Tb10 in ovarian
carcinoma cell lines, reduced cellular proliferation and movement,
and apoptosis was accelerated. Hence, Tb10 overexpression in
normal ovarian cells appears to act as a negative regulator of
carcinogenesis, though the exact mechanism is unclear. However,
Figure 3. The decrease in 2774 ovarian cancer cell migration and invasion as a result of Tb10 overexpression. (A) Subconfluent 2774
human ovarian cancer cells were infected with 10 MOI of Ad.TERT.LacZ or Ad.TERT.Tb10 for 12 hr. After re-suspension, cells were further incubated for
12 hr in the upper chamber of a TranswellH plate coated with a collagen monolayer for the migration assay or with double layer of collagen and
matrigel for the invasion assay. The results are expressed as a percentage of the vehicle control and are mean 6 SE (bars) of three
experiments. Significant differences from vehicle control group are denoted by an asterisk (*), P,0.05; a double asterisk (**), P,0.01 (B) The virus-
infected cells were also further incubated in a 35 mm m–Dish, low, with a culture-Insert (Ibidi) for 12 hr, and followed by observation of the direction
and speed of cell migration during wound-healing. The wound-healing results are expressed as a percentage of the vehicle control and are mean 6
SE (bars) of three experiments. Significant differences from vehicle control group are denoted by a double asterisk (**), P,0.01.
doi:10.1371/journal.pone.0035399.g003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e35399Figure 4. Induction of apoptosis by overexpression of Tb10 in 2774 ovarian cancer cells. (A) Subconfluent 2774 ovarian cancer cells were
maintained for 5 days in complete culture medium containing Ad.TERT.LacZ or Ad.TERT.Tb10 at an MOI of 10 or 100, and the MTT-bioassay was
performed daily. (B) On the second day after viral infection, a FACS Annexin V/propidium iodide (PI) assay was performed according to the
manufacturer’s (Clontech) protocol. Representative scatter plots are showing the distribution of annexin V- and PI-stained cells. In top panels, the X-
axis (FL1-H) indicates annexin V–FITC fluorescence detected at 518 nm, and the Y-axis (FL2-H) indicates PI fluorescence detected at 620 nm. As the
lower left (LL) quadrant indicates live cells, the upper left (UL) quadrants indicate necrotic cells, the upper right (UR) quadrats indicate late apoptotic
cells, and lower right (LR) quadrant indicates early apoptotic cells (top panels), the results are expressed as a percentage of total cell numbers and are
mean 6 SE (bars) of three individual experiments. Significant differences from vehicle group are denoted by an asterisk (*), P,0.05; a double asterisk
(**), P,0.01.
doi:10.1371/journal.pone.0035399.g004
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sequestration like Tb10, ectopic expression of Tb10 in our
experimental system may lead to increased activity of ß-thymosins
and subsequent perturbation of actin dynamics. This concept is
supported by reports that Tb4 and Tb10 act on vessel development
in a complementary way in vivo [6] and that the imbalance of G-
Figure 5. Ad.TERT.Tb10-induced selective apoptotic morphological changes in human primary ovarian cancer cells, but not in
normal fibroblasts. (A) Co-cultures of subconfluent primary human ovarian cancer cells and fibroblasts were exposed to 10 MOI of Ad.TERT.Tb10 for
24 hr, and then immunocytochemistry was performed to observe the nuclear morphological changes induced by Tb10 expression. Differential
interference contrast (DIC) image was merged with 4,6-diamidino-2-phenylindole (DAPI) staining (blue) and Alexa 488 staining (green) to evaluate
nuclear fragmentation by Tb10 expression. Arrows indicate nuclear fragmentations. (B) Co-cultured subconfluent primary human ovarian cancer cells
and fibroblasts were exposed to 10 MOI of Ad.TERT.Tb10 for over 90 hr, and morphological changes were then observed using a real-time imaging
system. White arrows indicate selective morphological features of apoptosis, such as cell plasma membrane blebbing, cytoplasmic vacuolization, and
cell shrinkage (after 10 hr), followed by loss of cell-to-cell interactions (after 15 hr). And black arrows tracking one of fibroblasts indicate that
fibroblasts are actively moving about even until 90 hr.
doi:10.1371/journal.pone.0035399.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e35399Figure 6. Ad.TERT.Tb10-induced increase in cancer-specific FAS expression in human ovarian cancer cells, resulting in apoptosis. (A)
Subconfluent 2774 human ovarian cancer cells were exposed to Ad.TERT.LacZ or Ad.TERT.Tb10 at an MOI of 10 for 48 hr and followed by next
experiments such as RT-PCR and Western blotting to detect FAS (CD95) mRNA and protein expression, respectively. (B) Subconfluent primary human
ovarian cancer cells co-cultured with fibroblasts were also exposed to 10 MOI of Ad.TERT.Tb10 for 24 hr and followed by immunocytochemistry.
Specific FAS/CD95 antibody staining (Alexa 488, green) was merged with differential interference contrast (DIC) images and nuclear staining images
(DAPI, blue) using imaging software. White and orange arrows indicate fibroblasts and ovarian cancer cells, respectively. (C) Cells were exposed to
Ad.TERT.LacZ or Ad.TERT.Tb10 at an MOI of 10 with or without caspase inhibitor (zVAD, 40 mM), and actin polymerization inhibitor (cytochalasin D,
1 mg/ml) for 48 hr. The 2774 ovarian cancer cells were then stained according to the commercial caspase 3 assay kit protocol (Thermo) and imaged
using a Thermo Scientific Cellomics ArrayScan high-content screening (HCS) reader. In the bar graph, the values representing a percentage of the
vehicle control is followed by the ratio between the area of caspase 3 activation and the area of the nucleus. And the results are mean 6 SE (bars) of
three different experiments. Significant differences from vehicle group are denoted by a double asterisk (**), P,0.01 (left bar graph). Cytotoxicity
under the same conditions was determined in cultured ovarian cancer cells using the alamar Blue (AB) assay as an in vitro alternative model. The
results are expressed as a percentage of the vehicle control and are mean 6 SE (bars) of three experiments. Significant differences from vehicle
control group are denoted by an asterisk (*), P,0.05; a double asterisk (**), P,0.01 (right bar graph)
doi:10.1371/journal.pone.0035399.g006
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considered a possible strategy for cancer research and gene
therapy with Tb10. We, therefore, manufactured a recombinant
adenovirus, Ad.TERT.Tb10, to use for human gene therapy and
to elucidate the mechanism of Tb10 in ovarian cancer prevention.
Recombinant adenovirus systems are versatile for gene expres-
sion studies and therapeutic applications, and many researchers
have used recombinant adenoviruses with great success over the
years. However, their low specificity is a disadvantage limiting the
usefulness of these vectors as in vivo therapeutic agents. Vectors
that combine high infectivity with cancer cell-specific expression
are, therefore, needed. Several studies have shown that human
telomerase reverse transcriptase (hTERT) is highly expressed in
most tumor tissues but not in normal tissues. For example, hTERT
promoter activity is higher in human and murine cancer cells
derived from lung, colon, liver, breast, ovary, and brain [42–47].
Conversely, they have shown that the hTERT promoter is inactive
in normal human fibroblasts [42], and normal human epithelial
cells from trachea [42], mammary [47], and ovary [45,48].
Therefore, we examined the role of Tb10 in ovarian cancer using
a recombinant adenovirus (Ad.TERT.Tb10). Ad.TERT.Tb10 was
constructed by insertion of the Tb10 gene under the control of the
hTERT promoter into the adenovirus p-shuttle plasmid to obtain
cancer-specific expression, and it was compared with Ad.TER-
Figure 7. Ad.TERT.Tb10-induced decrease in mitochondria membrane potential (MMP) and increase in ROS production in 2774
human ovarian cancer cells. (A) Cells were exposed to Ad.TERT.LacZ (10 MOI), Ad.TERT.Tb10 (10 MOI), and actin polymerization inhibitor
(cytochalasin D, 1 mg/ml) for 48 hr, and then a mitochondrial membrane potential (MMP) assay was performed. The MMP assay was performed using
the MMP assay kit protocol (Thermo), and the results were imaged using a Thermo Scientific Cellomics ArrayScan high-content screening (HCS)
reader. (B) Cells were exposed to Ad.TERT.LacZ (10 MOI), Ad.TERT.Tb10 (10 MOI) with or without anti-cancer agents, such as paclitaxel (taxol, 5 mg/ml)
and cisplatin (platinum, 10 mg/ml), for 48 hr. The results were compared to those from other treatments, for example, each anti-cancer agent or actin
polymerization inhibitor (cytochalasin D, 1 mg/ml). The levels of intracellular reactive oxygen species (ROS) were detected by a fluorescence ELISA
system with the oxidation-sensitive fluorescent probe 2, 7-dichlorofluorescein diacetate (DCF-DA). In addition to the ROS assay, an MTT-bio assay was
also performed under the same conditions. The all results are expressed as a percentage of the vehicle control and are mean 6 SE (bars) of three
experiments. Significant differences from vehicle control group are denoted by an asterisk (*), P,0.05; a double asterisk (**), P,0.01.
doi:10.1371/journal.pone.0035399.g007
The Function of Thymosin ß10 on Ovarian Cancer
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e35399T.LacZ as a control. In a co-culture model of primary human
ovarian cancer cells and normal fibroblasts, b-galactosidase driven
by the hTERT promoter was expressed in ovarian cancer cells
only but not in normal fibroblasts. Cytotoxic and apoptotic
morphological changes were absent from the normal fibroblasts
treated with 10 MOI of Ad.TERT.LacZ over a 7-day period, in
contrast to the ovarian cancer-specific apoptosis induced by
treatment of cells with 10 MOI of Ad.TERT.Tb10 over a 10-hour
period. Moreover, we found that the cancer-specific expression of
Tb10 from Ad.TERT.Tb10 was accompanied by the elevated
expression of Fas, resulting in cancer-specific apoptosis. Therefore,
we considered that the anticancer effect of Ad.TERT.Tb10
appeared to be associated with the overexpression of Tb10 rather
than non-specific viral toxicity.
Previous studies have reported that a high level of ROS has
a positive effect on cancer development and proliferation [49–56].
However, we found that the actin sequestration by overexpression
of Tb10 was due to the mitochondrial dysfunction and ROS
elevation, by which apoptosis signaling was activated. The idea
that cancer cells are vulnerable to attack by ROS is supported by
the therapeutic use of widely accepted anticancer drugs such as
taxol and cisplatin. Both of these drugs increase ROS generation
in 2774, and cotreatment of anticancer agents with Tb10 result in
an additive effect of ROS elevation and subsequent induction of
apoptosis. Therefore, the fate of the cancer cell seems to be
determined by the ROS balance. Mild elevation of ROS may help
cancer development, but excessive ROS elevation in cancer cells
under some stresses such as Tb10 overexpression and treatment of
anticancer drugs appears to stimulate apoptotic signals.
In addition to induction of apoptosis, Tb10 overexpression
potently reduced motility in the 2774 ovarian cancer cells, and this
effect was independent of apoptosis induction. In the 2774 ovarian
cancer cells, apoptosis was induced much later than in primary
ovarian cancer cells. Ad.TERT.Tb10-induced apoptosis in prima-
ry ovarian cancer cells and immortalized cancer cell lines such as
2774, OVCAR3, and SKOV3, occurred 10- and 48-hours later,
respectively. As the assays of invasion and migration were
performed prior to observation of apoptosis, we suggest that
Tb10 overexpression in ovarian cancer may have beneficial cell-
killing effects of primary tumor cells as well as metastatic cells.
Our findings indicate that the anti-cancer activity of Tb10 may
be due to ROS generation. Furthermore, Tb10 and anti-cancer
agents, such as taxol and cisplatin, had a synergistic effect on
cancer cell death. We also found that cancer-specific over-
expression of Tb10 driven by the hTERT promoter resulted in
cancer-selective apoptosis through amplification of FAS signaling.
This study provides insight into the mechanism underlying the
anti-cancer effects of Tb10 in ovary, which may prove useful for
the development of effective ovarian cancer therapies without side
effects.
Materials and Methods
Ethics Statement
The works using human sample were received the written
consent of a patient and approved by the Korean Association of
Institutional Review Board (KAIRB).
Cell Lines and Primary Cell Culture
The human ovarian cancer cell line 2774 was obtained from the
American Type Culture Collection (ATCC), and primary human
ovarian cancer and fibroblast cells were isolated from patients with
grade III endometrioid adenocarcinoma (cancer) and co-cultured
on glass surfaces. Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS; Upstate Biotechnology, Lake
Placid, NY, USA), and 100 U/ml penicillin/streptomycin (Invi-
trogen).
Viral Vectors
The recombinant adenovirus, ‘‘Ad.TERT.Tb10,’’ was con-
structed according to the standard procedure used in the
AdEasy
TM Adenoviral Vector System (Stratagene, La Jolla, CA,
USA). The recombinant adenovirus Ad.TERT.Tb10 plasmid was
generated by recombination of the modified pShuttle plasmid
(pSuttle.TERT.Tb10) and backbone plasmid pAdEasy-1 in E.coli
BJ5183. Subsequently, the recombinant adenoviral plasmid DNA
was isolated using a plasmid DNA isolation kit (Axygen, Union
City, CA, USA), linearized by a Pac I restriction enzyme digest,
and then transfected into 293A cells. The manufactured
recombinant adenovirus was purified using an adenovirus
purification kit (Cell Biolabs, San Diego, CA, USA).
Reverse Transcription Polymerase Chain Reaction (PCR),
and Real-time PCR
Cells were washed twice with ice-cold PBS, and the total RNA
was extracted from the samples with Trizol (Invitrogen). Reverse
transcription (RT) was performed using 1 mg total RNA and the
SuperScript
TM II RT kit (Invitrogen). First-strand cDNA synthesis
from total RNA was completed by heating for 60 min at 42uC and
15 min at 70uC. One microliter of RT reaction mixture was then
amplified using the Taq polymerase kit (Invitrogen) to produce
cDNA using an iCycler PCR detection system (Bio-Rad Labora-
tories, CA, USA). Furthermore, 10 ml of RT reaction mixture was
used as a template for RT-PCR using the iQ
TM SYBRH Green
Supermix kit (Bio-Rad, Invitrogen) using an iCycler iQ real-time
PCR detection system (Bio-Rad). The primers used for PCR were
as follows: Ad-TERT upstream primer, 59-AAATTTGGGCG-
TAACCGAGT-39; Ad-TERT downstream primer, 59-AT-
GAGGCCAACATCTGGTCA-39;T b10 upstream primer, 59-
GTCGACATGGCAGACAAACCAGA-39;T b10 downstream
primer, 59-GATGGACACGAGCCACAAAGATCT-39; Ad-E1a
upstream primer, 59-CGGGATCCCCACCATGAGACATAT-
TATCTGCCACG-39; Ad-E1a downstream primer, 59-
CGGAATTCTTACTCGAGGTCAATCCCTTCCTGCACC-
39; FAS/CD95 upstream primer, 59-CTCCAACCT-
TAAATCCTGAAACAG-39; and FAS/CD95 downstream prim-
er, 59-CGAACAAAGCCTTTAACTTGACTT-39. The PCR
procedure comprised a denaturing step of 94uC for 3 min is
followed by 30 cycles of denaturation at 94uC for 1 min, annealing
at a primer pair-specific temperature (Ad.TERT, 53uC; Tb10,
61uC; Ad-E1a, 44uC; FAS/CD95, 53uC) for 1 min, and extension
at 72uC for 1 min.
Immunohistochemical Staining for Thymosin b10
Paraffinized human ovarian tumor samples were used for
immunohistochemical staining (IHC). The xylene deparaffinized
samples were stained with polyclonal thymosin b10 antibody
(Abcam,). This stain was detected using avidin–biotin–horseradish
peroxidase complex (HRP, Abcam). In brief, the deparaffinzed
samples were fixed with retrieval solution (citrate buffer; 10 mM
sodium citrate buffer, 0.05% Tween 20, pH 6.0) at 95uC for
20 min and subsequently maintained at 4uC for 30 min. The fixed
specimen slides were washed three times with 1x PBS, and then
incubated with 5% FBS at 25uC for 1 hr. Subsequently, the
samples were exposed to polyclonal thymosin b10 antibody (1:50;
Abcam) diluted with 3% FBS solution at 4uC overnight, incubated
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room temperature (RT), and further incubated with HRP at 25uC
for 1 hr. Finally, the specimen slides were developed using the
chromagen 3,39-diaminobenzidine tetrahydrochloride (DAB;
DAKO, Glostrup, Denmark). Cell nuclei were counterstained
with Mayer’s hematoxylin (Sigma, St. Louis, MO, USA).
Immunocytochemical Staining
After exposure to recombinant adenovirus, primary or 2774
ovarian cancer cells were washed twice with PBS and fixed in 4%
paraformaldehyde for over 10 min. Then, cells were washed three
times in ice-cold PBS, blocked with 3% bovine serum albumin
(BSA) in PBS for 1 hr, then incubated with polyclonal anti-
thymosin b10 (Abcam) or polyclonal anti-human Fas ligand/
TNFSF6 antibody (R&D systems, Minneapolis, MN, USA) for
1.5 hr. A further incubation with a secondary Alexa488 anti-
rabbit antibody (Invitrogen) was performed for 45 min. The cells
were washed three times in ice-cold PBS again and then stained by
4’,6-diamidino-2-phenylindole (DAPI, Invitrogen). Finally, the
slides were mounted using Crystal/Mount
TM reagent (Biomeda
Corp, Poster City, CA, USA) and examined for fluorescence using
a BX51TR microscope (Olympus, Japan) connected to a digital
camera (Olympus, DP50).
Cell Migration, Invasion, and Wound-healing Assays
After exposure to recombinant adenovirus for 12 hr, 2774
ovarian cancer cells were placed in the upper chambers of
a TranswellH plate (Corning Costar, Cambridge, MA, USA) and
coated with collagen only or with a collagen matrigel to assess
migration and invasion, respectively. Then they were soaked in
1 ml culture media for a further 12 hr. Cells were removed from
the upper side of the filter. Those cells that had either migrated to
or invaded the underside of the filter were counted with the aid of
a microscope. Experiments were performed in triplicate. In
addition to the migration assay using TranswellH plates,
recombinant adenovirus-exposed cells were replaced in a 35-mm
m–Dish, low, with a culture insert (Ibidi, Munich, Germany) for
12 hr, and then the direction and speed of cell migration during
wound-healing was monitored.
Cell Viability
Mitochondrial function of cultured 2774 ovarian cancer cells
was measured using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide (MTT) conversion assay (Mosmann T,
1983). MTT was purchased from Sigma. This assay, which
provides a general indication of cell viability, takes advantage of
the conversion of the yellow MTT compound to purple formazan
crystals by mitochondrial succinate dehydrogenase in viable cells.
Briefly, MTT was diluted in 0.1 M phosphate buffered saline
(PBS) and added to cells grown in 96-well plates at a final
concentration of 0.25 mg/ml. After incubation for 2 hr at 37uC
with MTT, the culture medium was removed. The precipitated
formazan was solubilized with dimethyl sulfoxide (DMSO) and
quantified spectrophotometrically at 595 nm. In addition to the
MTT-bio assay for cell viability, the Alamar Blue assay was also
performed to quantitatively assess the viability of the 2774 ovarian
cancer cells. The oxidized form of Alamar Blue has a dark blue
color and little intrinsic fluorescence. When taken into cells, the
dye becomes reduced and turns red. This reduced form of Alamar
Blue is highly fluorescent. The extent of this conversion, which is
a reflection of cell viability, can be quantified by optical density or
fluorescence measurements for greater sensitivity. The colorimet-
ric change of Alamar Blue at 570 nm, as compared to the
reference wavelength, 600 nm, is proportional to the number of
viable cells.
Annexin V-FITC Flow Cytometric Analysis
The annexin V-FITC apoptosis detection kit (Invitrogen) was
used to detect early and late apoptosis. Annexin V has a strong
affinity for phosphatidyl serine, which is externalized in the
membranes of apoptotic cells. In brief, 2774 ovarian cancer cells
were exposed to recombinant adenovirus for 48 hr, washed in
PBS, and resuspended in binding buffer (HEPES–NaOH 10 mM
pH 7.4, 144 mM NaCl and 25 mM CaCl2). Annexin V-FITC
(0.2 mg/ml) and propidium iodide (PI, 0.05 mg/ml) were added,
and the cells were incubated in the dark for 20 min. Fluorescent
activated cell sorting was performed using a FACS Calibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), and at
least 10,000 events were recorded and represented as dot plots.
Real-time Imaging
Subconfluent co-cultured primary ovarian cancer cells and
fibroblasts were grown on a 35-mm confocal dish (SPL, Kyeong-
ki, Korea) in the presence of recombinant adenovirus (10 MOI of
Ad.TERT.Tb10). The growing cells were photographed every
30 min for 90 hr by means of a live cell confocal microscopy
system (Carl Zeiss, Jena, Germany).
Gel Electrophoresis and Western Blotting
Western blot analysis was performed to determine FAS/CD95
protein expression. After washing 1X with cold PBS, cells were
harvested from culture dishes in 200 ml of lysis buffer (Tris 50 mM
at pH 7.4, 10 mM EDTA, 1% Tween-20, 10 mM leupeptin, and
1 mM phenylmethyl-sulfonyl fluoride), and the cell lysates were
homogenized by a brief sonication. Total cell lysates, containing
equal amounts of protein, were subjected to 10% SDS-PAGE at
50 mA and were then transferred onto nitrocellulose membranes
for 1.5 hr at 50 V. Non-specific binding was blocked by incubation
of the membranes in a solution containing 5% non-fat dried milk
in T-TBS buffer (20 mM Tris buffer; 0.5 M NaCl, 0.5% Tween-
20). Blots were incubated with polyclonal anti-human Fas Ligand/
TNFSF6 antibody (R&D systems, Minneapolis, MN, USA,
1:1000) followed by incubation with horseradish peroxidase
(HRP) antibody (1:5,000, Abcam). The blots were visualized using
the Amersham ECL
TM GST Western Blotting Detection reagent
and developed using the ECL system (Amersham Pharmacia,
Piscataway, NJ, USA).
High Content Forster Resonance Energy Transfer
Screening Analysis
To evaluate the change of mitochondria membrane potential
(MMP) activity and caspase 3 activity caused by infection of
human ovarian cancer cells with recombinant adenovirus (Ad.-
TERT.Tb10), we performed high-content Forster resonance
energy transfer screening analysis using a Cellomics ArrayScan
VTI HCS Reader (Thermo Scientific, Pittsburgh, PA, USA). The
MMP and caspase 3 assays were performed according the Thermo
Scientific Cellomics HCS Reagent kit instructions (Thermo
Scientific). Briefly, various reagents, including ROS inhibitors,
a caspase inhibitor, an actin polymerization inhibitor, as well as
a recombinant adenovirus, were added to the 2774 human ovarian
cancer cells growing on a 96-well plate in DMEM supplemented-
with 10% fetal bovine serum (FBS). After 48 hr, the cells were
washed twice with PBS and stained according to the standard
procedure outlined in the CellomicsH HCS Reagent Series
Multiparameter Cytotoxicity 2 kit (Thermo Scientific) and the
The Function of Thymosin ß10 on Ovarian Cancer
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e35399CellomicsH Caspase 3 Activation Kit (Thermo Scientific) to
evaluate MMP activity and caspase 3 activity, respectively.
Fluorescent cells were photographed at the following wavelengths
(excitation/emission): 350/461 nm (Hoechst Dye), 554/576 nm
(Mitochondrial Dye), and 562/572 nm (DyLightTM549-Conju-
gated goat anti-rabbit IgG for Caspase 3). The data were acquired
for four fields in each well (n=6) of the plate using the620
objective. The data obtained were analyzed using the t-test for
independent samples.
ROS Assay
Intracellular ROS formation was measured by fluorescence
using 29,79-dichlorofluorescein diacetate (DCF-DA). DCF-DA
was purchased from Invitrogen. This nonfluorescent dye is
freely permeable to cells, and in cells, DCF-DA is de-esterified
to its ionized free acid (DCFH), which then reacts with ROS to
form a fluorescent 29,7 9- dichlorofluorescein dye (DCF). In
brief, cells were loaded with 20 mM of DCF-DA and 20%
Pluronic F-127 for 30 min, and then kept at room temperature
for an additional 30 min to allow for complete dye de-
esterification. For DCF measurement, excitation and emission
were monitored at 490 nm and 530 nm, respectively, using
a fluorescence plate reader (Victor V plate reader, Perkin
Elmer, Wellesley, MA, USA).
Statistical Analysis
The data represent mean 6 SE from three independent
experiments except where indicated. Data were analyzed using
Student’s t-test at a significance level of P,0.01 (**) or P,0.05 (*).
Supporting Information
Movie S1 Ad.TERT.Tb10-induced selective apoptotic
morphological changes in human primary ovarian
cancer cells, but not in normal fibroblasts. Co-cultured
subconfluent primary human ovarian cancer cells and fibroblasts
were exposed at 10 MOI of Ad.TERT.Tb10, and morphological
changes were observed at every 30 min using a real-time imaging
system. White dotted circles are indicating selective morphological
features of apoptosis, such as cell plasma membrane blebbing,
cytoplasmic vacuolization, and cell shrinkage (after 10 hr),
followed by loss of cell-to-cell interactions (after 15 hr). And black
dotted circle tracking one of many fibroblasts indicates that they
are not only alive but also actively moving for over 90 hrs.
(AVI)
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